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The UK Food Standards Agency convened a group of expert scientists to review current research investigating folate bioavailability. The
workshop aimed to overview current research and establish priorities for future research. Discrepancies were observed in the evidence base
for folate bioavailability, especially with regard to the relative bioavailability of natural folates compared with folic acid. A substantial
body of evidence shows folic acid to have superior bioavailability relative to food folates; however, the exact relative bioavailability
still needs to be determined, and in particular with regard to mixed diets. The bioavailability of folate in a mixed diet is probably not
a weighted average of that in the various foods consumed; thus the workshop considered that assessment of folate bioavailability of
whole diets should be a high priority for future research.
Folate bioavailability: Folic acid supplementation: Food Standards Agency workshop: Nutrition research
The UK Food Standards Agency (FSA) convened a work-
shop on 27 January 2003 on folate bioavailability. The
results from recently completed studies were presented,
both FSA and non-FSA funded, and the workshop was
chaired by Professor Jess Gregory, University of Florida,
USA. The aim of the workshop was to determine where
this work has taken us and where further work should be
concentrated, as well as acting as a vehicle for dissemina-
tion. The research recommendations will feed into the
future direction of FSA-funded nutrition research, and
may also be of value in guiding other funders.
Background
Folate is a generic term for a B-group vitamin found widely
in foodstuffs. There is a large family of naturally occurring
folates; mostly reduced tetrahydropteroylglutamates, often
in polyglutamyl form and usually one-carbon substituted.
Folate vitamers in foods occur mainly as reduced methyl-
and formyl-tetrahydropteroylpolyglutamates (Perry, 1971;
Scott & Weir, 1976). Folic acid (pteroylmonoglutamic
acid) is the synthetic form used in supplements and food
fortification. Folates function coenzymically in the transfer
and processing of one-carbon units and play an important
role in nucleotide synthesis, methylation, and gene
expression (Shane, 1995). Examples are: (i) the synthesis
of thymidine, which is essential for the de novo construc-
tion or repair of DNA; (ii) the remethylation of plasma
homocysteine to methionine; (iii) the ‘site-specific’ methyl-
ation of the cytosine base in DNA, which regulates gene
expression. Folates play a key role in disease prevention,
with low folate status associated with increased risk for car-
diovascular disease, neural tube defects (NTD), colorectal
cancer and dementia (Medical Research Council Vitamin
Study Research Group, 1991; Boushey et al. 1995;
Blount et al. 1997).
The issue of the bioavailability of food folates became
apparent with the publication of the classic paper by
Tamura & Stokstad (1973). Although aspects of their
methodology have been criticized, this study showed that
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the bioavailability of folate in a wide variety of foods was
incomplete and highly variable. Bioavailability can be a
major determinant of nutritional status when folate intakes
are in the marginal range.
Bioavailability is defined in many ways, most of which
focus on the efficiency of intestinal absorption. Post-
absorptive metabolism and excretion processes can affect
bioavailability in certain contexts, but this is mainly rele-
vant to intakes of folic acid (or other supplements) at
doses that exceed the requirement and the metabolic
capacity. Recent terms such as bioefficacy and bioconver-
sion (van Lieshout et al. 2003) extend the concept of bio-
availability. Regardless of definition though, bioavailability
depends on many factors and is not a constant (Bronner,
1993).
The bioavailability of folic acid (both supplemental and
in fortified foods) is almost always substantially higher
than the net bioavailability of naturally occurring food
folate. Factors thought to affect folate bioavailability
include: incomplete release from plant cellular structure
(van het Hof et al. 1999; Castenmiller et al. 2000); entrap-
ment in the food matrix during digestion (Pfeiffer et al.
1997); instability during digestion (for example, tetrahy-
drofolate (THF); Seyoum & Selhub, 1998); partial inhi-
bition of deconjugation by other dietary constituents
(especially organic acids) (Bhandari & Gregory, 1992;
Wei et al. 1996; Wei & Gregory, 1998); other dietary con-
stituents increasing folate stability during digestion (for
example, folate-binding proteins; Jones & Nixon, 2002);
possibly other constituents such as ascorbate, or other redu-
cing agents. Whether the degree of conjugation of polyglu-
tamyl folates affects bioavailability remains unclear in
view of conflicting data (Gregory, 1997).
Genetic factors have also been suggested to affect folate
bioavailability, such as: a history of NTD-affected preg-
nancy (Davis et al. 1995; Neuhouser et al. 1998; Boddie
et al. 2000); or the presence of a glutamate carboxypepti-
dase II single nucleotide polymorphism (Devlin et al.
2000), although this was not confirmed more recently
(Lievers et al. 2002; Vargas-Martinez et al. 2002).
Determination of folate status
Serum and plasma folate concentrations are a responsive
indicator of folate status and are commonly used in acute
studies. Erythrocyte folate concentrations are a less respon-
sive indicator, but are considered to be the best index of
long-term status. The lifespan of the erythrocyte is 120 d,
and folates are retained in the erythrocyte for the duration
of its life; thus, less than 1 % of circulating erythrocytes are
replaced daily (Gregory, 2001). Intervention studies, there-
fore, need a minimum duration of 3–4 months when asses-
sing this index (Ward et al. 1997).
Plasma total homocysteine (tHcy) concentrations are
also used as an indicator of folate status; elevated levels
of tHcy are considered to be a risk factor for cardiovascular
disease (Homocysteine Studies Collaboration, 2002) and
NTD (Mills et al. 1995). The remethylation of homocys-
teine to methionine by methylenetetrahydrofolate
(MTHF) reductase (MTHFR) is dependent on an adequate
supply of folate; thus, low folate status results in elevated
tHcy concentrations. Several other B vitamins are also
required for the remethylation of homocysteine: cobalamin
(B12), vitamin B6 and riboflavin (B2), B6 (McKinley et al.
2001) and B12 nutritional status (Quinlivan et al. 2002)
may also affect tHcy concentrations.
Other factors as well as B vitamins may also affect
tHcy concentrations; for example, alcohol, physical
activity, dietary fibre (Mennen et al. 2002) and coffee
(Verhoef et al. 2002). Furthermore, the modification to
dietary patterns has been suggested to be more effective
than increasing folate-rich foods alone in lowering tHcy
(Appel et al. 2000). The C677T MTHFR polymorphism
also influences tHcy concentrations. Its prevalence is
related to ethnicity: the homozygous TT genotype is
about 10 % in Caucasians (though it may be population-
dependent, and is about 20 % or more in some Italian
and US Hispanics) and only a few percent in Africans
and Afro-Americans (Botto & Yang, 2000). The homozy-
gous form (TT) is associated with elevated tHcy levels of
typically 25 % (Engbersen et al. 1995).
The studies presented as part of this workshop investi-
gated the efficacy of different folates on folate status;
these included chronic feeding trials and more acute
stable isotopic studies.
Chronic feeding studies
Professor Helene McNulty presented the results from an
FSA-funded project comprising several studies examining
the biological responses in healthy subjects to intervention
with food folates or folic acid, as well as determining food
folate concentrations. The main findings from the analysis
of food folates and the effects of cooking on folate reten-
tion in foods (Mckillop et al. 2002) were:
. The boiling, but not steaming, of green vegetables
(broccoli and spinach) resulted in significant losses
(.50 %) of folates from the vegetables into the
water. Boiling potatoes or grilling beef did not signifi-
cantly affect their folate content.
. By using a tri-enzyme predigest (protease, amylase and
conjugase) in the determination of food folate content
(composite meals, spinach, broccoli, potato and beef),
significantly higher values (1·3- to 6-fold) than the pub-
lished values were obtained (Pentieva et al. 2002).
In all intervention trials, any homocysteine-lowering
due to vitamin B6 or B12 deficiency was corrected by
pre-treatment with physiological doses of these vitamins
before commencing the folate intervention. Subjects
were healthy males aged 18–45 years who were not con-
sumers of B-vitamin supplements or fortified foods, and
not homozygous for the thermolabile (C677T) variant
of the MTHFR gene. The main findings from the inter-
vention trials were:
. Subjects (n 20) were administered with incremental
doses of folic acid (100, 150, 200 and 400mg/d) for a
total period of 32 weeks. Intervention resulted in sig-
nificant incremental increases in serum folate and cor-
responding significant decreases in plasma tHcy, with
the maximum reduction in tHcy observed in response
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to 200mg/d; no further significant lowering was
observed in response to 400mg/d administered for 14
weeks, despite significant increases in serum folate
concentration (Ward et al. 2002)
. Subjects (n 24) received 200mg folic acid/d for 12 weeks
as either a supplement or as fortified bread. Both treat-
ments resulted in equivalent reductions in tHcy and
increases in serum folate concentrations, demonstrating
the high bioavailability of folic acid in fortified bread.
. Subjects (n 45) were supplemented for 30 d with one of
four treatments: folic acid (200mg/d); spinach folate
extract (200mg/d); yeast folate extract (200mg/d); or
placebo (McKillop et al. 2003). Folic acid supplemen-
tation raised serum folate levels and reduced tHcy
levels to a larger extent than the other treatments; rela-
tive bioavailability was calculated as 31 % for spinach
and 53 % for yeast.
. Subjects (n 73) were supplemented for 30 d with 0·2 mg
folate/d as either: folic acid (n 18); spinach drink (n 12)
or meal (n 6); yeast drink (n 13) or meal (n 6); or placebo
(n 18). All treatments raised folate status as determined
by serum folate and tHcy concentrations; however,
folic acid supplementation was more effective than
either spinach or yeast, which showed overall relative
bioavailabilities of 33–44 % (spinach) and 45–62 %
(yeast) (MPA Hannon-Fletcher, NC Armstrong, JM
Scott, M Ward, JJ Strain, K Pentieva, AA Dunn, AM
Molloy, M Scullion and H McNulty, unpublished
results).
In general, there was no evidence that foods that have
a greater percentage of folate in the conjugated form (for
example, yeast, which contains virtually all polygluta-
mates) were less bioavailable than those with less (for
example, spinach, which contains about 50 % polygluta-
mates; egg, which contains 0 % polyglutamates). The
food matrix did not appear to exert an effect on folate
bioavailability, in that similar results were found whether
or not the food was administered with the food matrix
intact. Estimations of relative folate bioavailability
tended to be lower when food folates were provided as
a meal compared with as a drink, suggesting that the pre-
sence of other (non-folate) foods ingested at the same
time adversely affects the bioavailability of food folate.
Professor Pierpaolo Mastroiacovo presented results
from a 13-week placebo-controlled randomized trial
(P Mastroiacovo, E Carnovale, A Turrini, L Mistura,
S Ruggeri, E Camilli, R Ricci, O Genovese, B Zappacosta,
S Persichilli, A Minucci, G Andria, A Boninconti, unpub-
lished results) investigating in 149 free-living subjects
(18–60 years, mean 40·4 years) with moderate hyperhomo-
cysteine (mean 12·8mmol/l) using three strategies for
increasing daily folate: dietary counselling to add around
200mg natural folate/d; 200mg folic acid/d; 200mg
5-MTHF/d. The primary outcome was the effect on tHcy
concentrations; the secondary outcome was the effect on
erythrocyte folate concentrations. Randomization was
performed by MTHFR C677T genotype stratum. The
main findings from the study were:
. The mean total daily intake of folate in the four ran-
domized arms was: 350mg/d in the dietary-counselling
group; 420mg/d in the 5-MTHF group; 403mg/d in the
folic acid group; 220mg/d in the placebo group. The
dietary assessment of subjects was conducted using a
food frequency questionnaire; in the diet group the veg-
etables and fruits that contributed most to folate intake
were Swiss chard, French beans, artichoke, spinach,
asparagus and broccoli (among vegetables) and
orange, orange juices, kiwi and mandarin (among
fruits).
. The absolute and relative mean variations of plasma
tHcy (geometric mean adjusted on starting values)
and the ratio v. the placebo group were respectively:
(a) enriched diet: 23·2mmol, 223·0 %, ratio 0·79;
(b) 5-MTHF: 23·1mmol, 222·3 %, ratio 0·80;
(c) folic acid: 23·3mmol, 224·1 %, ratio 0·77;
(d) placebo: 20·9mmol, 27·5 %, ratio 1·00
(reference).
. The subgroup analysis by MTHFR C677T genotype did
not show relevant differences among the three geno-
types (TT, CT, CC) or among the homozygous TT indi-
viduals and the others (CT, CC).
. The mean erythrocyte folate levels increased signifi-
cantly during the 13 weeks in the three treated
groups, but not in the placebo group. There was a stat-
istically significant difference between the treated
groups (marginal for the 5-MTHF group) and placebo
group. Mean erythrocyte folate levels were highest
after supplementation with folic acid, but not signifi-
cantly higher than the levels observed in the dietary-
counselling group.
Increasing natural folate intake by dietary counselling
decreased tHcy concentrations to an extent similar to that
observed with 200mg folic acid/d or with 200mg
5-MTHF/d. The effect seems similar to that observed
with higher doses of folic acid (Homocysteine Lowering
Trialists’ Collaboration, 1998), which may be due to the
high subject baseline levels of tHcy; an important determi-
nant of the size of the tHcy-lowering response. The effect
obtained with an enriched diet of natural folate is clinically
relevant since one out of three individuals had a decrease
of one-quarter of his starting tHcy. Although subjects
with the common polymorphism MTHFR C677T had
higher initial tHcy levels, this did not influence the treat-
ment effect. If these results are confirmed by other studies,
population dietary modification may be an effective strat-
egy to decrease tHcy and possibly reduce the risk of
cardiovascular disease in the population.
Dr Ian McDowell presented results from a study (Moat et
al. 2003) that measured B-vitamin status and plasma tHcy in
126 healthy subjects aged 20–63 years (forty-two CC,
forty-two CT and forty-two TT MTHFR genotypes) at base-
line and following three sequential interventions of 4
months each: placebo plus natural diet; supplement of
400mg folic acid/d plus natural diet; increased dietary
folate (including folic acid-fortified foods) to 400mg/d.
This study was primarily designed to assess the effect on
homocysteine of dietary or low-dose folate supplements in
relation to MTHFR genotype combined with an assessment
of its effect on vascular endothelial function (Pullin et al.
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2001). Riboflavin status was evaluated as an additional
study. The main findings from this study were:
. Plasma tHcy was significantly higher in those with the
TT genotype and responded to increased folate intake
with dietary or supplemental folate to similar extents.
Subjects with the TT genotype were particularly
responsive to enhanced folate intake (Ashfield-Watt
et al. 2002).
. At baseline and following nutritional interventions,
lower riboflavin status was associated with increased
plasma tHcy concentrations. tHcy was 2·6mmol/l
higher in the lowest plasma riboflavin quartile com-
pared with the highest (P,0·02) and was 4·2mmol/l
higher in the highest erythrocyte glutathione reductase
activation coefficient quartile compared with the
lowest (P,0·001). This effect was not restricted to
those with the T allele (observed in TT and CT, but
not CC).
. There was a high prevalence of low riboflavin status in
the study population and folic acid supplementation
appeared to exacerbate this. This suggests that folic
acid supplementation alone may increase the rate of
turnover of flavins, thereby exacerbating any tendency
to riboflavin deficiency.
Folate and riboflavin appear to interact to lower plasma
tHcy. The effect of folate is most pronounced in those with
the TT gentoype but that of riboflavin may be unrelated to
the MTHFR genotype. However, other studies (Jacques
et al. 2002; McNulty et al. 2002) report that any effect
of riboflavin status is confined to the TT genotype and
Yamada et al. (2001) observed that the TT variant releases
its riboflavin-derived cofactor FAD much faster than the
wild-type enzyme.
Alida Melse-Boonstra presented results from a series of
studies undertaken at Wageningen Centre for Food
Sciences, The Netherlands. The main studies were:
A double-blind placebo-controlled dose-finding trial to
determine the lowest folic acid dose that lowers tHcy
concentrations adequately in healthy older adults (316
men and women, 50–75 years). Subjects were randomly
assigned to one of seven treatment groups: 50, 100, 200,
400, 600 and 800mg folic acid, or placebo daily for 12
weeks. Groups were stratified for baseline tHcy concen-
trations. A maximal reduction in tHcy concentration was
observed at 0·4 mg/d; 0·2 mg/d resulted in a reduction in
tHcy of 77 % of that observed with 0·4 mg/d (van Oort
et al. 2003).
Subjects (180 men and women, 50–75 years) were ran-
domized to one of three treatment groups receiving
daily either 323 nmol (about 200mg/d) monoglutamyl
folic acid, 262 nmol (about 285mg/d) heptaglutamyl
folic acid or a placebo capsule. Serum and erythrocyte
folate concentrations, and tHcy concentrations, were
measured after 2 and 12 weeks of intervention. The
relative bioavailability of heptaglutamyl folic acid
was 64 (95 % CI 52, 75) % based on serum folate
and 68 (95 % CI 51, 84) % based on erythrocyte
folate. The relative bioefficacy, that is the ability of
folic acid to lower homocysteine concentrations, of
heptaglutamyl folic acid was found to be 106 (95 %
CI 77, 134) %.
These studies show that in older adults, daily
supplementation with folic acid effectively lowers tHcy
concentrations, with no further reductions being observed
at doses above 0·4 mg/d. Also, the polyglutamyl form of
folic acid had lower bioavailability than the monoglutamyl
form.
Stable isotopic studies
The advantage of isotopic labelling studies is their
specificity; however, a disadvantage can be sensitivity,
due to the dose of a stable isotopically labelled folate
tracer required to yield measurable enrichment of blood
or urine folates. This limitation can be overcome,
in part, by using protocols involving repeated small
doses.
Alida Melse-Boonstra presented results from a pilot
study using a newly developed dual-label stable-isotope
protocol: three subjects (aged 20–30 years) took
200 nmol (about 90mg/d) [13C11]monoglutamyl folic
acid and 200 nmol (about 190mg/d) [13C6]hexaglutamyl
folic acid daily for 10 d in the form of a capsule. Fasting
blood samples were collected at days 3, 6 and 10 after
supplement administration and analysed for concen-
trations of [13C11]folate, [
13C6]folate and unlabelled
folate. This was done by a liquid chromatography-MS–
MS method. The relative bioavailability of hexaglutamyl
folic acid was calculated by taking the ratio of plasma
enrichments of [13C6]folate and [
13C11]folate at 10 d.
Results revealed a bioavailability of 70 (range 66–72) %
of hexaglutamyl folic acid as compared with the monoglu-
tamyl form.
The pilot study has been repeated in twenty subjects
(men and women, aged 20–50 years) and preliminary
data analysis indicates comparable results with the pilot
study. This confirms the findings from the chronic feeding
study and suggests that folate bioavailability can be studied
successfully with this dual-label stable-isotope protocol
with multiple dosing.
Paul Finglas presented the results from an FSA-
funded project (Wright et al. 2003) involving acute
stable-isotope studies using a direct liquid chromatog-
raphy–MS technique, and intrinsic stable-isotope-labelled
spinach folates. 13C-labelled oral test folate isolates (folic
acid, n 14; 5-formyltetrahydrofolic acid, n 16) and 15N-
labelled spinach folates (mainly 5-methylTHF and 5-for-
mylTHF, n 14) were administered to volunteers, and the
plasma folate response (both total and labelled) was ana-
lysed by HPLC and liquid chromatography–MS over
the following 8 h. The main findings from these studies
were:
There was a marked difference in the absorption and
metabolism of folic acid v. the natural folates: the rate
of appearance in plasma was slower and the total
plasma folate response was less following administration
of folic acid. Also, administration of all forms resulted in
an increase in non-test dose unlabelled plasma folate,
and this was less so for folic acid.
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Mathematical modelling of the data suggested that the
liver sequesters a proportion of all newly absorbed
folate (the first-pass effect), which was significantly
greater following the oral administration of folic acid
(about 70 %) than for natural folates (about 50 %, or
lower).
There was a strong correlation (r 0·94; P,0·001)
between the labelled plasma response to an oral dose
of labelled folic acid and fasting baseline plasma folate
concentration, which was not observed for the natural
folates. It was suggested, therefore, that folic acid may
not be reduced and methylated at the mucosal level
but appears unchanged in the hepatic portal vein where
it is removed more efficiently than any 5-methylTHF
derived from other reduced folates (5-formylTHF or
spinach folate). It was suggested that physiological
doses of folic acid transferred from mucosal cells to
the hepatic portal vein are removed in their entirety
(i.e. 100 %) on the first-pass to the liver, and all the sub-
sequent labelled 5-methylTHF plasma response is
entirely a function of enterohepatic recirculation.
It appears, therefore, that folic acid is metabolized dif-
ferentially by the liver as compared with natural folates;
more of the folic acid form was taken up by the liver
from the portal vein suggesting the liver to be the pri-
mary site for its subsequent reduction and methylation.
This has implications for acute methods of determining
relative folate bioavailability that rely upon measuring
plasma folate levels in response to the oral administ-
ration of folates relative to that of a ‘reference dose’ of
folic acid. However, whether folic acid is methylated
and reduced by the liver still requires further
investigation.
Discussion
There are discrepancies in the evidence base for folate
bioavailability, especially with regard to the relative bio-
availability of natural folates compared with folic acid.
A substantial body of evidence shows folic acid to
have superior bioavailability relative to food folates;
however, the exact relative bioavailability still needs to
be determined, and in particular with regard to mixed
diets. The use of dietary folate equivalents, in principle,
is a good way to express dietary recommendations
because it adjusts for the apparent difference in bioavail-
ability between dietary folate and added folic acid. How-
ever, the reliability of this approach is questionable
because of the uncertainties in the relative bioavailability
of each. The bioavailability of folate in a mixed diet is
probably not a weighted average of that in the various
foods consumed. Thus:
the screening of various individual foods should be a
low priority except in mechanistic studies or to verify
efficacy;
assessment of folate bioavailability in food classes is a
higher priority;
assessment of whole diets is a high priority (for example,
Sauberlich et al. 1987).
With regard to tHcy lowering, it is particularly important
to assess the impact of the whole diet, as it is affected by a
number of dietary factors.
An added complication to the assessment of folate intake
is that the accuracy of food composition tables is variable.
This was highlighted at the workshop with the application
of improved methodologies for food folate determination.
The FSA is currently assessing the impact of this on its
published food composition tables.
Priorities and research recommendations identified at
the workshop
The workshop recommended that:
there should be an increased focus on whole diets;
mechanisms affecting bioavailability are a priority for
research;
improved methods are needed for the assessment of
bioavailability of naturally occurring folates.
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